Alcon Inc. (ALC) AI Stock Analysis

Alcon Inc., headquartered in Geneva, Switzerland, specializes in research, development, manufacturing, distribution, and sales of eye care products. The company operates two segments: Surgical and Vision Care. The Surgical division delivers equipment, intraocular lenses, surgical solutions, and diagnostic tools, including the Centurion Vision System, LenSx femtosecond laser, and NGENUITY 3D visualization system. The Vision Care segment offers contact lenses under brands such as DAILIES AquaComfort PLUS and Air Optix, alongside ocular health products treating dry eye, glaucoma, and ocular allergies, as well as ocular vitamins and redness relievers.

Between FY2021 and FY2025, annual revenue expanded from $8.29B to $10.40B, reflecting a 5-year revenue CAGR of 8.8%. Operating margin improved from 7.0% in FY2021 to 13.1% in FY2025, while net income rose from $376.0M to $980.0M over the same timeframe. In FY2025, revenue grew 4.9% with an EPS of $3.06. Over the trailing twelve months, revenue totaled $10.86B with an operating margin of 14.6% and a net profit margin of 5.9%. In the quarter ending June 30, 2026, quarterly revenue increased 8.7% year-over-year, while quarterly earnings fell 44.6%.

As of June 30, 2026, Alcon held $1.46B in cash and short-term investments against total debt of $5.30B, leading to net debt of $3.84B. The current ratio stood at 2.09, and the debt-to-equity ratio was 0.25 on shareholders' equity of $21.59B. Free cash flow was $1.61B in FY2025, generated from operating cash flow of $2.27B. In FY2025, cash deployment included $663.0M for capital expenditures, $723.0M for share buybacks, and $166.0M in dividends paid.

Alcon trades at a trailing P/E of 50.1x, above the 24.6x median of its US-listed Healthcare peers, but its forward P/E of 16.2x sits below the peer median of 17.3x. Enterprise value is $35.65B with an EV/EBITDA of 13.1x, compared to the peer median of 12.0x, and its price-to-sales ratio is 2.9x versus the peer median of 4.1x. Over the past 1 year, the stock returned -11.8%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, the stock returned -13.7% against an 83.0% gain for the benchmark.

Alcon provides an annual forward dividend of $0.36 per share, yielding 0.54% with a payout ratio of 11.0%. The company pays dividends on an annual frequency and has delivered consecutive dividend payments for 6 years. Its last ex-dividend date occurred on May 6, 2026.

Wall Street analysts hold 17 Strong Buy, 4 Buy, 5 Hold, 1 Sell, and 0 Strong Sell ratings on Alcon. The mean price target is $82.73, representing a 25.0% premium over the last close of $66.18. Consensus estimates anticipate FY2026 EPS of $3.50 on revenue of $11.09B, followed by FY2027 EPS of $3.96 on revenue of $11.76B. Alcon beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 10, 2026.

This page is an AI-written research summary of Alcon Inc. (ALC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALC income statement, ALC balance sheet, ALC key metrics, ALC analyst forecast, ALC chart. See the ALC stock overview for the latest quote and news.